129 related articles for article (PubMed ID: 15351171)
21. Reliability of estrogen receptors in predicting response to antiestrogens.
Valavaara R
Oncology (Williston Park); 1997 May; 11(5 Suppl 4):14-8. PubMed ID: 9165501
[TBL] [Abstract][Full Text] [Related]
22. First-line endocrine therapy alone could be a reasonable treatment option for hormone-positive, HER2-positive metastatic breast cancer.
Peron J; Tredan O; Ray-Coquard I; Bachelot T; Labidi Galy SI; Favier B; Treilleux I; Guastalla JP
Bull Cancer; 2012 Feb; 99(2):E18-25. PubMed ID: 22257781
[TBL] [Abstract][Full Text] [Related]
23. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.
Knoop AS; Lænkholm AV; Jensen MB; Nielsen KV; Andersen J; Nielsen D; Ejlertsen B;
Eur J Cancer; 2014 May; 50(8):1412-21. PubMed ID: 24675287
[TBL] [Abstract][Full Text] [Related]
24. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
; Colleoni M; Gelber S; Goldhirsch A; Aebi S; Castiglione-Gertsch M; Price KN; Coates AS; Gelber RD
J Clin Oncol; 2006 Mar; 24(9):1332-41. PubMed ID: 16505417
[TBL] [Abstract][Full Text] [Related]
25. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
Lancet; 1998 May; 351(9114):1451-67. PubMed ID: 9605801
[TBL] [Abstract][Full Text] [Related]
26. A prognostic table to guide practitioners advising patients on adjuvant systemic therapy in early breast cancer.
Stotter A
Eur J Surg Oncol; 1999 Aug; 25(4):341-3. PubMed ID: 10419700
[No Abstract] [Full Text] [Related]
27. Re: five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.
Panasci LC; Melnychuk D
J Natl Cancer Inst; 1997 Nov; 89(21):1631-2. PubMed ID: 9362168
[No Abstract] [Full Text] [Related]
28. [Effectiveness of adjuvant therapy for patients with early-stage (I-IIa) breast cancer].
Semiglazov VF
Vopr Onkol; 1998; 44(2):137-41. PubMed ID: 9615814
[No Abstract] [Full Text] [Related]
29. The role of aromatase inhibitor (AI) in the treatment of breast cancer.
Irawan C; Abdulmuthalib
Acta Med Indones; 2005; 37(1):43-8. PubMed ID: 15879638
[No Abstract] [Full Text] [Related]
30. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
31. Cyclin D1 expression and patient outcome after tamoxifen therapy in estrogen receptor positive metastatic breast cancer.
Han S; Park K; Bae BN; Kim KH; Kim HJ; Kim YD; Kim HY
Oncol Rep; 2003; 10(1):141-4. PubMed ID: 12469160
[TBL] [Abstract][Full Text] [Related]
32. Tumor angiogenesis in women with node-positive breast cancer.
Folkman J
Cancer J Sci Am; 1995; 1(2):106-8. PubMed ID: 9166461
[No Abstract] [Full Text] [Related]
33. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer.
Foekens JA; Diamandis EP; Yu H; Look MP; Meijer-van Gelder ME; van Putten WL; Klijn JG
Br J Cancer; 1999 Feb; 79(5-6):888-94. PubMed ID: 10070886
[TBL] [Abstract][Full Text] [Related]
34. Is fulvestrant more effective than tamoxifen for treating ER-positive breast cancer in postmenopausal women?
Raina V
Nat Clin Pract Oncol; 2004 Nov; 1(1):20-1. PubMed ID: 16264793
[No Abstract] [Full Text] [Related]
35. [Results of tamoxifen treatment in patients with advanced breast cancer].
Rolski J; Pawlicki M; Zemełka T; Pernal J
Pol Merkur Lekarski; 1996 Oct; 1(4):271-3. PubMed ID: 9156943
[TBL] [Abstract][Full Text] [Related]
36. Is axillary lymph node dissection necessary in elderly patients with breast carcinoma who have a clinically uninvolved axilla?
Martelli G; Miceli R; De Palo G; Coradini D; Salvadori B; Zucali R; Galante E; Marubini E
Cancer; 2003 Mar; 97(5):1156-63. PubMed ID: 12599220
[TBL] [Abstract][Full Text] [Related]
37. The influence of tamoxifen treatment on the oestrogen receptor in metachronous contralateral breast cancer.
Kaas R; Peterse JL; Hart AA; Voogd AC; Rutgers EJ; van Leeuwen FE
Br J Cancer; 2003 Mar; 88(5):707-10. PubMed ID: 12618879
[TBL] [Abstract][Full Text] [Related]
38. Endocrine therapy in breast cancer.
Johnson AE
Lancet; 1996 Mar; 347(9003):761. PubMed ID: 8602017
[No Abstract] [Full Text] [Related]
39. Estrogen receptors and anti-estrogen therapies.
Buluwela L; Constantinidou D; Pike J; Ali S
Cancer Treat Res; 2004; 119():271-92. PubMed ID: 15164882
[No Abstract] [Full Text] [Related]
40. Tamoxifen may be an effective adjuvant treatment for BRCA1-related breast cancer irrespective of estrogen receptor status.
Foulkes WD; Goffin J; Brunet JS; Bégin LR; Wong N; Chappuis PO
J Natl Cancer Inst; 2002 Oct; 94(19):1504-6. PubMed ID: 12359859
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
